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Abstract
Increased stiffness characterizes the early change in the arterial wall with subclinical 
atherosclerosis. Proteins inducing arterial stiffness in diabetes and hypercholester-
olaemia are largely unknown. This study aimed at determining the pattern of pro-
tein expression in stiffening aorta of diabetic and hypercholesterolaemic mice. Male 
Ins2+/Akita mice were crossbred with ApoE−/− (Ins2+/Akita: ApoE−/−) mice. Relative aortic 
distension (relD) values were determined by ultrasound analysis and arterial stiff-
ness modulators by immunoblotting. Compared with age- and sex-matched C57/BL6 
control mice, the aortas of Ins2+/Akita, ApoE−/− and Ins2+/Akita:ApoE−/− mice showed 
increased aortic stiffness. The aortas of Ins2+/Akita, ApoE−/− and Ins2+/Akita:ApoE−/− 
mice showed greater expression of VCAM-1, collagen type III, NADPH oxidase and 
iNOS, as well as reduced elastin, with increased collagen type III-to-elastin ratio. The 
aorta of Ins2+/Akita and Ins2+/Akita:ApoE−/− mice showed higher expression of eNOS 
and cytoskeletal remodelling proteins, such as F-actin and α-smooth muscle actin, 
in addition to increased glycosylated aquaporin (AQP)-1 and transcription factor 
NFAT5, which control the expression of genes activated by high glucose-induced hy-
perosmotic stress. Diabetic and hypercholesterolaemic mice have increased aortic 
stiffness. The association of AQP1 and NFAT5 co-expression with aortic stiffness 
in diabetes and hypercholesterolaemia may represent a novel molecular pathway or 
therapeutic target.
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1  | BACKGROUND
Compared with non-diabetic individuals, diabetic patients suffer 
more aggressive, rapidly progressive atherosclerosis often with ear-
lier complications, such as arterial stiffness.1,2 This is because altered 
glucose metabolism in diabetes can modify and increase the impact 
of comorbidities, such as hypercholesterolaemia.3 In these patients 
at high risk of cardiovascular events, the identification of clinical and 
molecular markers that allow an early diagnosis of atherosclerosis is 
essential. Arterial stiffening is also an established clinical marker of 
early subclinical atherosclerosis.2,4,5
The arterial stiffness has been shown to be associated with hy-
pertension6 and kidney disease.7 The underlying mechanisms may be 
attributed to (a) endothelial dysfunction leading to vasoconstriction; 
(b) oxidative stress and inflammatory factors;8 and (c) vascular calci-
fications.9 However, proteins that promote the arterial stiffening in 
diabetes and hypercholesterolaemia are less known. Pathogenetic 
mechanisms and biomarkers of early-stage vascular abnormalities, 
such as arterial stiffening, can be identified through animal models of 
diabetes and hypercholesterolaemia.10 Cytoskeletal reorganization 
and arterial remodelling are adaptive responses to altered biome-
chanical stress. Reorganization of the vascular cytoskeleton is caus-
ally connected with arterial stiffening and contractile dysfunction.11 
It can be favoured by an increase in wall stress or biomechanical 
stretching caused by high blood pressure.11 In diabetes, arterial re-
modelling can occur as the result of a chronic increase in wall stress 
or biomechanical stretching due to high glucose-induced hyperos-
molar stress, often fluctuating in uncontrolled diabetes. We have 
previously shown that concentrations of glucose up to 30.5 mmol/L, 
attainable under hyperglycaemic conditions, induce an up-regu-
lation of F-actin, α-smooth muscle actin (ASMA) and cytoskeletal 
remodelling in human-induced pluripotent stem (iPS) cells.12 These 
effects appeared to be mediated through an aquaporin isoform 1 
(AQP1)- and transcription factor nuclear factor of activated T cells 5 
(NFAT5)-dependent hyperosmolar stress which, through this mech-
anism, promotes cell migration.12 Thus, hyperosmolar stress can act 
as a most important biophysical factor that promotes cytoskeletal 
remodelling and the migration of vascular cells, such as vascular 
smooth muscle cells (VSMCs), within the arterial media. Directed 
migration of VSMCs requires a polarized reorganization of the cyto-
skeleton actin. From the six mammalian actin genes, the expression 
of VSMC-specific cytoskeleton actin ASMA appears to be regulated 
by both CArG promoter elements, such as the transcriptional coact-
ivator myocardin,13 and NFAT5.14 NFAT5, a rel/NF-κB family mem-
ber, is a transcription factor activated by hyperosmolar stress, which 
regulates the expression of osmosensing genes, including those in-
volved in cell migration and cytoskeletal remodelling.12,15-18
In the present research, we sought to determine the impact of 
hypercholesterolaemia and diabetes on arterial wall stiffness in the 
aortas of genetic diabetes and hypercholesterolaemia mice mod-
els. We also analysed gene expression underlying arterial stiffening 
at the protein level, including the product of genes responsive to 
biomechanical stretch, such as high glucose-induced hyperosmolar 
stress. Understanding changes in protein expression and molecu-
lar circuits activated by concomitantly present risk factors, such as 
hypercholesterolaemia and diabetes, may indicate new targets for 




All chemicals were purchased from Sigma St Louis MO, unless oth-
erwise specified.
2.2 | Experimental animals
Ins2+/Akita heterozygous, C57BL/6J and apoE−/− homozygous muta-
tion (apoE-knockout) mice were originally obtained from The Jackson 
Laboratory (Bar Harbor, ME)28, 29. All mice were on a C57BL/6J back-
ground. All procedures were approved by the Institutional Ethics 
Committee for Animal Research (Protocol number 11/2012/CEISA/
COM). All animal experiments complied with the ARRIVE guide-
lines and were carried out in accordance with the United Kingdom 
Animals (Scientific Procedures) Act, 1986 and associated guidelines, 
the European Union (EU) Directive 2010/63/EU for animal experi-
ments and the United States of America (USA) National Institutes 
of Health guide for the care and use of Laboratory animals (NIH 
Publications No. 8023, revised 1978).
2.3 | Generation of Ins2+/Akita: ApoE−/− mice and 
study population
Diabetic male Ins2+/Akita: ApoE+/+ (Ins2+/Akita heterozygous mice) 
were crossed with non-diabetic female Ins2+/+Akita: ApoE−/− mice 
(F0). The resulting F1 generation consisted of heterozygous apoE± 
(Ins2+/Akita:apoE± and Ins2+/+:apoE±) mice. From this F1 generation, 
diabetic male Ins2+/Akita:apoE± mice were crossed with non-diabetic 
female Ins2+/+:apoE−/− mice. The resulting F2 generation consisted 
of homozygous apoE−/− (Ins2+/Akita:apoE−/− and Ins2+/+:apoE−/−) and 
heterozygous apoE± (Ins2+/Akita:apoE± and Ins2+/+: apoE±) mice. 
Subsequently, diabetic male Ins2+/Akita:apoE−/− mice (from F2 
generation) and non-diabetic female Ins2+/+:apoE−/− were set up 
as breeding pairs to produce an F3 generation of diabetic Ins2+/
Akita:apoE−/− mice and non-diabetic control Ins2+/+:apoE−/− mice. 
For the present study, we used male mice from the F3 generation 
(diabetic and non-diabetic control) because male Ins2+/Akita mice 
exhibit a more severe and homogeneous diabetic phenotypes com-
pared with female mice.19 The study population comprised male 
wild-type C57BL/6 mice (bodyweight: 15 ± 4 g, age: 3 months; 
n = 3), male Ins2+/Akita diabetic mice (bodyweight: 11 ± 2 g, n = 3), 
male apoE−/− mice (bodyweight: 21 ± 5 g, n = 3) and male Ins2+/
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Akita:apoE−/− mice (bodyweight: 19 ± 2 g, n = 3). All animals were 
specific pathogen-free and kept in a temperature-controlled envi-
ronment in a ventilated rack with a 12-h:12-h light:dark cycle. Mice 
had free access to water and standard rodent chow diet (Teklad 
2018; Harlan Laboratories), which contains <0.1% cholesterol and 
fat as 18% of total calories. Genotypes were determined by poly-
merase chain reaction (PCR) amplification of tail DNA using proto-
cols provided by The Jackson Laboratory. The diabetic phenotype 
was confirmed in mice at 4-5 weeks after birth by blood glucose 
values >250 mg/dL with a hand-held glucometer (Contour; Bayer 
Health Care) measured with a drop of blood from tail puncture. The 
hypercholesterolaemic phenotype was confirmed by total choles-
terol values >150 mg/dL. The disease penetrance was 100% in mice 
with the Ins2Akita mutation.20
2.4 | Biochemical assays
Plasma glucose, total cholesterol and triglyceride concentrations 
were measured using an enzymatic colorimetric method by Vitros 
DT60 II Chemistry System (Ortho-Clinical Diagnostics) according to 
the manufacturer's instructions (Table 1).
2.5 | Mouse ultrasound imaging
Transthoracic ultrasound imaging on wild-type C57BL/6 male mice 
and sex/age-matched Ins2+/Akita, apoE−/− and Ins2+/Akita:apoE−/− mice 
was performed to determine systolic and diastolic aortic diameters. 
Two-dimensional and M-mode echocardiographic images were re-
corded and analysed using a portable ultrasound apparatus (Esaote) 
equipped with a 21-MHz linear probe. Images were obtained in the 
parasternal long-axis view. Aortic diameter instantaneous values 
were derived from B-mode images and were recorded in late systole 
and late diastole using edge detection.21 Mean diameter (Dm) and 
relative distension (relD) values (this latter considered as a surrogate 
marker for arterial stiffness) were evaluated from the obtained diam-
eter waveforms; relD was calculated as (Ds − Dd)/Dd and expressed 
as a percentage (where Ds is the diameter in systole and Dd the di-
ameter in diastole). After measurements, mice were killed, and their 
aorta excised for protein extraction.
2.6 | Immunoblotting
Total proteins from aortas, harvested from wild-type C57BL/6 male 
mice and sex/age-matched Ins2+/Akita, apoE−/− and Ins2+/Akita:apoE−/− 
mice, were isolated, electroblotted and incubated with the fol-
lowing primary and secondary antibodies: (a) mouse monoclonal 
anti-collagen type III (dilution 1:2000, Sigma Aldrich); (b) mouse 
monoclonal anti-elastin (dilution 1:2000, Sigma Aldrich); (c) mouse 
monoclonal anti-AQP1 (dilution 1:600, Santa Cruz Biotechnologies); 
(d) rabbit polyclonal anti-F-Actin (dilution 1:500, Santa Cruz); (e) 
mouse policlonal anti-eNOS (dilution 1:2500, BD Transduction 
Laboratories, San Jose, CA); (f) rabbit polyclonal anti-VCAM-1 (di-
lution 1:600, Santa Cruz); (g) rabbit polyclonal anti-ICAM-1 (dilu-
tion 1:600, Santa Cruz); (h) mouse monoclonal anti-IL-1β (dilution 
1:200, R&D Systems); (i) mouse monoclonal anti-TNF-α (dilution 
1:200, R&D Systems); (j) rabbit monoclonal anti-NADPH oxidase 
(dilution 1:1000, Abcam); (k) rabbit polyclonal anti-NFAT5 (dilution 
1:600, Santa Cruz); (l) mouse policlonal iNOS (dilution 1:2500, BD 
Transduction Laboratories); (m) rabbit monoclonal anti-NFAT5 (dilu-
tion 1:600, Santa Cruz); (n) mouse monoclonal anti-ASMA (dilution 
1:2000, Sigma Aldrich); (o) mouse monoclonal anti-β-actin (Sigma); 
and (p) mouse anti-GAPDH (dilution 1:5000, Ambion), as previously 
described.22
2.7 | Statistical analysis
Groups were compared by one-way analysis of variance followed by 
Scheffé's test for multiple comparisons. Statistical significance was 
defined as P < .05.
3  | RESULTS
3.1 | Aortic stiffness
To develop a murine model that can be used to study the role of 
diabetes and hypercholesterolaemia in aortic stiffness and in its 
protein expression, diabetic hypercholesterolaemic male Ins2+/
Akita:apoE−/− mice and non-diabetic hypercholesterolaemic female 
Ins2+/+:apoE−/− were crossed to produce diabetic hypercholester-
olaemic Ins2+/Akita:apoE−/− mice (Table 1). Three-month-old apoE−/− 
and Ins2+/Akita mice had significantly lower relative distension (relD) 
values than non-diabetic non-hypercholesterolaemic control mice 
(Figure 1). The combination of the two comorbidities further re-
duced aortic distension: compared with Ins2+/Akita mice and apoE−/− 
mice, relD values were more than halved in Ins2+/Akita:apoE−/− mice 
(Figure 1).
3.2 | Structural proteins
Collagen and elastin are the main structural proteins related to aortic 
stiffness. Abnormalities in the quantity and quality of collagen and 
elastin contribute to aortic stiffening.23 The aortas of 3-month-old 
apoE−/− and Ins2+/Akita mice had significantly higher levels of colla-
gen type III (Figure 2A) and lower levels of elastin (Figure 2B), with 
increased collagen type III-to-elastin ratio (Figure 2C) than non-di-
abetic, non-hypercholesterolaemic control mice. The combination 
of the two comorbidities further modified the expression of these 
proteins and their ratio, as levels of collagen type III and elastin were 
higher and lower in Ins2+/Akita:apoE−/− mice compared with Ins2+/Akita 
mice and apoE−/− mice, respectively (Figure 2).
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3.3 | VCAM-1
An increased expression of pro-inflammatory cytokines and adhe-
sion molecules has been suggested to contribute to collagen quality 
abnormalities, which can destabilize collagen fibres in the vascular 
wall.24,25 While there were no apparent changes in the expression 
of monocyte chemotactic protein-1, intercellular adhesion molecule 
(ICAM-1), tumour necrosis factor α and interleukin-1 in the aortas of 
apoE−/− and Ins2+/Akita mice (Figure 3B-D), the expression of vascular 
cell adhesion molecule (VCAM)-1 was significantly higher in Ins2+/
Akita mice and apoE−/− mice than in non-diabetic non-hypercholes-
terolaemic control mice (Figure 3A). The combination of the two 
comorbidities further increased the expression of VCAM-1, as the 
levels of this early pro-inflammatory adhesion protein were higher 
in Ins2+/Akita:apoE−/− mice compared with Ins2+/Akita mice and apoE−/− 
mice (Figure 3A).
3.4 | Nitric oxide synthase and NADPH oxidase
Increased formation of reactive oxygen species (ROS), includ-
ing peroxynitrite and nitrotyrosine, may contribute to abnor-
malities in the quality and destabilization of collagen fibres in 
the vascular wall.24,25 NAD(P)H oxidases produce O2
− and play a 
major role in ROS generation and oxidative stress. Increased ni-
tric oxide (NO) synthesis and reduced NO bioavailability, which 
leads to an increase in the NO pool, have been demonstrated in 
diabetes.26,27 Such excess of NO can cause the formation of per-
oxynitrite and nitrotyrosine. The aortas of 3-month-old apoE−/− 
and Ins2+/Akita mice had significantly higher levels of iNOS and 
NADPH oxidase than non-diabetic non-hypercholesterolaemic 
control mice (Figure 4A). The combination of diabetes and hyper-
cholesterolaemia further increased the expression of iNOS and 
NADPH oxidase, as the levels of these proteins were higher in 
C57/BL6 control Ins2+/Akita ApoE−/− Ins2+/Akita:ApoE−/−
Bodyweight, g 30 ± 0.5 22 ± 0.3 35 ± 0.7 26 ± 0.5
Fasted plasma 
glucose, mg/dL
110 ± 10 350 ± 20* 150 ± 15 390 ± 25*
Fasted plasma total 
cholesterol, mg/dL
105 ± 5 125 ± 8 425 ± 25* 625 ± 15*,§
Fasted plasma 
triglyceride, mg/dL
89 ± 7 105 ± 5 95 ± 6 103 ± 10
Note: Data shown are mean ± SD (n = 7 mice/group). To determine plasma glucose and lipid levels, 
tail blood samples were collected from each group of mice under fasting conditions.
Abbreviation: ApoE, apolipoprotein E.
*P < .05 vs C57/BL6 control mice. 
§P < .05 vs ApoE−/− mice. 
TA B L E  1   Phenotypic and biochemical 
characteristics of Ins2+/Akita, ApoE−/− and 
Ins2+/Akita:ApoE−/− mice
F I G U R E  1   Aortic stiffness. B-mode 
image sequence of the aortas was used 
to measure diameters and distension in 
Ins2Akita, ApoE−/− and Ins2Akita: ApoE−/− 
mice and from sex- and age-matched 
(3 months old) C57BL/6 non-diabetic 
non-hypercholesterolaemic control mice. 
A-D shows representative aorta images 
from sex- and age-matched (3 months 
old) C57BL/6 non-diabetic control mice 
(A), Ins2Akita mice (B), ApoE−/− mice (C) 
and Ins2Akita: ApoE−/− mice (D). E, The 
bar graph represents the mean ± SD of 
each relative distension (relD) values 
from 3 separate experiments. *P < .05 
vs C57BL/6 control mice; #P < .05 vs 
ApoE−/− mice; §P < .05 vs Ins2Akita mice 
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Ins2+/Akita:apoE−/− mice compared with Ins2+/Akita mice and apoE−/− 
mice (Figure 4A). Interestingly, only the aorta of Ins2+/Akita mice 
and Ins2+/Akita:ApoE−/− mice showed greater expression of eNOS 
(Figure 4B), suggesting that the up-regulation of both iNOS and 
eNOS may contribute to the increased NO pool in diabetic animal 
models with chronic hyperglycaemia.
F I G U R E  2   Expression of collagen type III and elastin. Western analysis of (A) collagen type III, (B) elastin expression and (C) collagen 
type III/elastin ratio in aortas from Ins2Akita, ApoE−/− and Ins2Akita: ApoE−/− mice and from sex- and age-matched (3 months old) C57BL/6 
non-diabetic control mice, with GAPDH serving as a loading control. The bar graph represents for each value the mean ± SD from 3 separate 






































































C57 Ins2+/Akita ApoE–/– Ins2/Akita : ApoE–/–
F I G U R E  3   Expression of VCAM-1, ICAM-1, IL-1β and TNF-α. Western analysis of (A) VCAM-1 (B) ICAM-1, (C) IL-1β and (D) TNF-α 
expression in aortas from Ins2Akita, ApoE−/− and Ins2Akita: ApoE−/− mice and from sex- and age-matched (3 months old) C57BL/6 non-diabetic 
control mice, with β-actin serving as a loading control. The bar graph represents for each value the mean ± SD from 3 separate experiments. 
*P < .05 vs C57BL/6 control mice; #P < .05 vs ApoE−/− mice; §P < .05 vs Ins2Akita mice and ApoE−/− mice; N = 8 mice/group
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3.5 | Cytoskeletal remodelling and expression of 
AQ1 and NFAT5
Arterial stiffening depends on cytoskeletal remodelling besides the 
accumulation of collagen. Cytoskeletal remodelling requires a polar-
ized reorganization of cytoskeletal actin, which involves the switch 
from globular actin (G-actin) to filamentous actin (F-actin) and the 
increased synthesis of VSMC-specific cytoskeletal ASMA. AQP1 
and NFAT5 are key proteins that regulate cellular homeostasis and 
the expression of hypertonicity-responsive genes, including the cy-
toskeleton-remodelling proteins F-actin and ASMA. In our murine 
model of diabetes and hypercholesterolaemia, only the aorta of 
Ins2+/Akita mice and Ins2+/Akita: ApoE−/− mice featured greater expres-
sions of ASMA (Figure 5A) and F-actin (Figure 5B). In parallel, the 
aorta of Ins2+/Akita mice and Ins2+/Akita: ApoE−/− mice showed a higher 
expression of glycosylated AQP1 (Figure 6A) and NFAT5 (Figure 6B).
4  | DISCUSSION
The current study demonstrates, for the first time in literature, 
that diabetic hypercholesterolaemic Ins2+/Akita: ApoE−/− mice are 
F I G U R E  4   Expression of iNOS, eNOS and NADPH oxidase. Western analysis of (A) iNOS, (B) eNOS and (C) NADPH oxidase expression in 
aortas from Ins2Akita, ApoE−/− and Ins2Akita: ApoE−/− mice and from sex- and age-matched (3 months old) C57BL/6 non-diabetic control mice, 
with β-actin serving as a loading control. The bar graph represents for each value the mean ± SD from three separate experiments. *P < .05 




























































F I G U R E  5   Expression of smooth 
muscle α-actin and F-actin. Western 
analysis of (A) smooth muscle α-actin 
(ASMA) and (B) F-actin expression 
in aortas from Ins2Akita, ApoE−/− and 
Ins2Akita: ApoE−/− mice and from sex- and 
age-matched (3 months old) C57BL/6 
non-diabetic control mice, with GAPDH 
serving as a loading control. The bar graph 
represents for each value the mean ± SD 
from three separate experiments. *P < .05 
vs C57BL/6 control mice; §P < .05 vs 
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characterized by increased arterial stiffness, in a manner associated 
with up-regulation of hypertonicity-responsive factors, such as AQ1 
and NFAT5, along with genes implicated in early inflammation and 
atherosclerosis, such as VCAM-1; cytoskeletal remodelling, such 
as F-actin and ASMA; endothelial dysfunction, such as iNOS and 
eNOS; and ROS generation, such as NADPH oxidase. These find-
ings suggest that (a) diabetes and hypercholesterolaemia add on and 
perhaps synergize in inducing aortic stiffening; (b) the biomechani-
cal stretch due to hyperglycaemia-induced hyperosmolar stress is 
specifically associated with aortic stiffening in diabetes; and (c) the 
hypertonicity-responsive transcription factor NFAT5 may play a key 
role in cytoskeletal remodelling and the subsequent arterial stiffen-
ing in diabetes.
Several factors can determine the increase in arterial stiffness, 
including decreased synthesis of elastin, increased collagen con-
tent and altered organization of elastic and collagen fibres.30,31 In 
the present study, we analysed the expression of collagen type III 
and elastin, which are the main structural proteins in the aortic wall, 
using Western analysis. In the aortas of diabetic and hypercholes-
terolaemic mice, we observed quantitative changes in the collagen 
and elastin contents, associated with the up-regulation of early 
pro-inflammatory and pro-atherogenic molecules, such as VCAM-1, 
and increased expression of nitric oxide synthases iNOS and eNOS, 
and NADPH oxidase. VCAM-1 is an early pro-inflammatory molecule 
that plays a key pro-atherogenic role in macrophage infiltration in 
the aortic wall.32 The up-regulation of iNOS and eNOS leads to in-
creased NO pool, with consequent formation of peroxynitrite and ni-
trotyrosine and increased oxidative stress in the aortic wall.26,27 The 
up-regulation of NADPH oxidases contributes to increased oxidative 
stress. Inflammation and oxidative stress have been shown to cause 
abnormalities in the quality of collagen fibres and a disarray of elastic 
fibres, due to elastolysis, which in turn impairs the elastic properties 
and the structural integrity of the aortic wall, leading to arterial stiff-
ening.33 Our results imply that diabetes and hypercholesterolaemia 
can both contribute to arterial stiffening at least in part through in-
flammation and increased oxidative stress in the aortic wall, leading 
to abnormalities in the quality of elastic and collagen fibres. These 
effects might be aggravated in ageing, although in our study we did 
not analyse the influence of ageing as a comorbidity.
Here, we provide the first evidence that NFAT5 and AQP1 are 
involved in the hypertonicity-related induction of arterial stiffening, 
since NFAT5 and AQP1 were increased in the aortas of diabetic Ins2+/
Akita mice exposed to high glucose-induced hyperosmolar stress, 
independent of the presence of hypercholesterolaemia. AQP1 is 
a water channel protein expressed widely in vascular endothelia 
and smooth muscle cells, where it increases cell membrane water 
permeability, as well as cell motility and migration, and regulates 
cellular homeostasis during osmolarity changes.12,34 NFAT5 is a 
transcription factor that regulates cellular homeostasis in response 
to hyperosmolar stress.15,35-38 Furthermore, NFAT5 regulates cell 
migration and the expression of cytoskeletal proteins, including ac-
tins, in several cell types, including VSMCs 14 and iPS cells under 
high glucose-induced hyperosmolar conditions.12 Thus, in condi-
tions of increased wall stress, such as arterial hypertension 11,39 or 
high glucose-induced hyperosmolar stress (as shown in the present 
study), NFAT5 contributes to the transition of VSMCs in the arterial 
media from quiescence to a motility state. These changes, together 
with wall thickening, characterize vascular remodelling and arterial 
stiffening,11,40 and are controlled by a wide range of transcription 
factors, such as AP-1, serum response factor and myocardin.41,42 In 
this context, we revealed that the hyperosmolar stretch-stimulated 
aortic wall responds by enhancing protein abundance of NFAT5, in 
line with observations made by other research groups.43 Our results 
suggest that cytoskeletal remodelling is a specific mechanism of aor-
tic stiffening in diabetes, with AQP1 and NFAT5 as main candidates 
involved in the specific cell signalling leading to an up-regulation of 
cytoskeleton-remodelling proteins.
We acknowledge some limitations of our study. First, ours is a 
cross-sectional study; thus, proteins that have been shown to be 
modulated by diabetes and hypercholesterolaemia could play a role 
as biomarkers rather than to be a direct cause of arterial stiffening. 
Thus, the mechanisms through which the up-regulated proteins 
F I G U R E  6   Expression of glycosylated 
AQP1 isoform and NFAT5. Western 
analysis of glycosylated AQP1 isoform 
and NFAT5 expression in aortas Ins2Akita, 
ApoE−/− and Ins2Akita: ApoE−/− mice and 
from sex- and age-matched (3 months 
old) C57BL/6 non-diabetic control mice, 
with GAPDH serving as a loading control. 
The bar graph represents for each value 
the mean ± SD from three separate 
experiments. *P < .05 vs C57BL/6 control 
mice and ApoE−/− mice; §P < .05 vs Ins2Akita 
mice and ApoE−/− mice; N = 8 mice/group
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shown here as associated with aortic stiffening operate on vascu-
lar disease are still incompletely worked out and deserve further in-
vestigation. Second, we still need to show that in vivo disruption of 
the AQP1/NFAT5 signalling, shown here as associated with aortic 
stiffening in diabetic mice, will mitigate in vivo vascular disease in 
response to high glucose. The absence of AQP1 and NFAT1 knock-
out mice having the comorbidities of diabetes and hypercholestero-
laemia complicates the performance of this type of experiments. A 
possible solution might be the use of specific drugs for AQP1 and 
NFAT5, currently not available.
5  | CONCLUSION
Diabetic and hypercholesterolaemic Ins2+/Akita: ApoE−/− mice develop 
aortic stiffening, associated with up-regulation of hypertonicity-
responsive gene such as AQ1 and NFAT5, along with genes impli-
cated in early inflammation and atherosclerosis, such as VCAM-1; 
cytoskeletal remodelling, such as F-actin and ASMA; endothelial 
dysfunction, such as iNOS and eNOS; and ROS generation such as 
NADPH oxidase. These changes in gene expression may be impor-
tant mechanisms leading to the development of arterial stiffening in 
diabetes and hypercholesterolaemia.
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